Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $159.61 million. The enterprise value is $79.84 million.
Important Dates
The last earnings date was Tuesday, May 19, 2026, after market close.
| Earnings Date | May 19, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Share Statistics
ORMP has 40.93 million shares outstanding. The number of shares has increased by 4.04% in one year.
| Current Share Class | 40.93M |
| Shares Outstanding | 40.93M |
| Shares Change (YoY) | +4.04% |
| Shares Change (QoQ) | +2.61% |
| Owned by Insiders (%) | 17.28% |
| Owned by Institutions (%) | 19.71% |
| Float | 28.57M |
Valuation Ratios
The trailing PE ratio is 1.55.
| PE Ratio | 1.55 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.68 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.73 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.45, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.45 |
| Quick Ratio | 6.28 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 58.16% and return on invested capital (ROIC) is -9.59%.
| Return on Equity (ROE) | 58.16% |
| Return on Assets (ROA) | -4.28% |
| Return on Invested Capital (ROIC) | -9.59% |
| Return on Capital Employed (ROCE) | -5.52% |
| Weighted Average Cost of Capital (WACC) | 11.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $27.30M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $21.85 million in taxes.
| Income Tax | 21.85M |
| Effective Tax Rate | 16.58% |
Stock Price Statistics
The stock price has increased by +87.74% in the last 52 weeks. The beta is 1.26, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +87.74% |
| 50-Day Moving Average | 3.86 |
| 200-Day Moving Average | 3.04 |
| Relative Strength Index (RSI) | 46.28 |
| Average Volume (20 Days) | 192,997 |
Short Selling Information
The latest short interest is 650,650, so 1.59% of the outstanding shares have been sold short.
| Short Interest | 650,650 |
| Short Previous Month | 576,933 |
| Short % of Shares Out | 1.59% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 5.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.25M |
| Pretax Income | 131.82M |
| Net Income | 109.19M |
| EBITDA | -14.13M |
| EBIT | -14.25M |
| Earnings Per Share (EPS) | $2.57 |
Full Income StatementBalance Sheet
The company has $65.84 million in cash and $761,000 in debt, with a net cash position of $83.05 million or $2.03 per share.
| Cash & Cash Equivalents | 65.84M |
| Total Debt | 761,000 |
| Net Cash | 83.05M |
| Net Cash Per Share | $2.03 |
| Equity (Book Value) | 238.28M |
| Book Value Per Share | 5.82 |
| Working Capital | 57.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.54 million and capital expenditures -$11,000, giving a free cash flow of -$8.55 million.
| Operating Cash Flow | -8.54M |
| Capital Expenditures | -11,000 |
| Depreciation & Amortization | 121,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.55M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.25, which amounts to a dividend yield of 6.28%.
| Dividend Per Share | $0.25 |
| Dividend Yield | 6.28% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.72% |
| Buyback Yield | -4.04% |
| Shareholder Yield | 2.24% |
| Earnings Yield | 67.04% |
| FCF Yield | -5.25% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on January 23, 2013. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
ORMP has an Altman Z-Score of 1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.69 |
| Piotroski F-Score | 1 |
